Skip to search formSkip to main contentSkip to account menu

7-ethyl-10-hydroxycamptothecin glucuronide

Known as: SN-38 glucuronide 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

CamptothecinGlucuronides
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
PURPOSE We aim to identify genetic variation, in addition to the UGT1A1*28 polymorphism, that can explain the variability in… 
Highly Cited
2006
Highly Cited
2006
Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN‐38 glucuronidation in Japanese patients with cancer
Pharmacogenetic testing for UDP‐glucuronosyltransferase (UGT) 1A1*28, a promoter variant of the UGT1A1 gene, is now carried out… 
Highly Cited
2004
Highly Cited
2004
UGT1A1 Haplotypes Associated with Reduced Glucuronidation and Increased Serum Bilirubin in Irinotecan‐administered Japanese Patients with Cancer
Highly Cited
2002
Highly Cited
2002
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
The metabolism of irinotecan (CPT-11) involves sequential activation to SN-38 and detoxification to the pharmacologically… 
Highly Cited
2002
Highly Cited
2002
Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice
Abstract.Purpose: The extensive and unpredictable biliary excretion of CPT-11 and its metabolites, SN-38 and SN-38 glucuronide… 
Highly Cited
2002
Highly Cited
2002
The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites.
Irinotecan hydrochloride (CPT-11) is an anticancer agent with unpredictable bouts of diarrhea as a dose-limiting toxic side… 
Highly Cited
2000
Highly Cited
2000
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
This study determined the disposition of irinotecan hydrochloride trihydrate (CPT-11) after i.v. infusion of 125 mg/m(2) (100… 
Highly Cited
1999
Highly Cited
1999
Irinotecan therapy in adults with recurrent or progressive malignant glioma.
PURPOSE To determine the activity, toxicity, and pharmacokinetics of irinotecan (CPT-11, Camptosar; Pharmacia & Upjohn, Kalamazoo… 
Highly Cited
1998
Highly Cited
1998
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.
PURPOSE In vitro synergy between cisplatin and irinotecan (CPT-11) has been reported. We designed a combination schedule of these… 
Highly Cited
1996
Highly Cited
1996
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and…
PURPOSE A pharmacokinetic study was performed during a phase II clinical trial of irinotecan (CPT-11) to confirm the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License